Boehringer Ingelheim announced the recipients of the 2025 Advancement in Equine Research Awards during the 71st annual American Association of Equine Practitioners Convention held in Denver, Colorado, from Dec. 6-10. The recipients were chosen based on their research proposals which included subject matter focused on equine infectious disease.
Recipients are the following:
Yosra Helmy, DVM, MVSc, PhD
Maxwell H. Gluck Equine Research Center, University of Kentucky
Lexington, KY
Carolyn E. Arnold, DVM, PhD, DACVS
School of Veterinary Medicine, Texas Tech University
Amarillo, Texas
*Ajran Kabir, DVM, MSc
Maxwell H. Gluck Equine Research Center, University of Kentucky
Lexington, KY
Nicola Pusterla, DVM, PhD, DACVIM, DAVDC
School of Veterinary Medicine, University of California
Davis, CA
*Alexis Smrekar, BS and Amanda de Mestre, BVSc, PhD, PGCAP
College of Veterinary Medicine, Cornell University
Ithaca, NY
*Graduate student recipients
“At Boehringer Ingelheim, we believe that the health and well-being of animals is pivotal to the success of moving life forward for both humans and animals. Our dedication and passion for the advancement of equine research makes Boehringer a global leader in its field,” said Steve Grubbs, DVM, PhD, DACVIM, Technical Manager for Boehringer. “Previous award recipients have made significant contributions to the advancement of research in equine infectious disease and we anticipate this year’s recipients will follow suit.”Those eligible to submit proposals were veterinarians, diagnosticians, and public and private researchers in the United States, Canada, and Mexico.
The Boehringer Advancement in Equine Research Awards program was launched in 2011 to support veterinary research that results in practical applications for insights into important equine infectious and non-infectious diseases. Nearly $1 million has been awarded to date in support of equine research.
About Boehringer Ingelheim – Animal Health Business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/us/animal-health.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Stay in the know! Sign up for EquiManagement’s FREE weekly newsletters to get the latest equine research, disease alerts, and vet practice updates delivered straight to your inbox.
